2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.94: Characteristics and Outcomes of Hispanic Patients With RET-Rearrangement Non-Small Lung Cancer (NSCLC) Treated in Real-World Practice

PP01.94: Characteristics and Outcomes of Hispanic Patients With RET-Rearrangement Non-Small Lung Cancer (NSCLC) Treated in Real-World Practice

Back to course

Pdf Summary

The study examines the characteristics and outcomes of Hispanic patients with non-small cell lung cancer (NSCLC) harboring RET fusions, treated across real-world settings in Latin America. RET fusions are rare genomic alterations in NSCLC, and while targeted therapies such as selective tyrosine kinase inhibitors (TKI) are approved in some regions, real-world data on Hispanic populations remain sparse.<br /><br />Conducted retrospectively, the study included 51 patients from five Latin American countries, undergoing various treatments including chemotherapy (CT), immune checkpoint inhibitors (ICIs), multikinase inhibitors (MKIs), and RET selective inhibitors (RETsi) over a period from January 2016 to April 2023. Molecular profiling through DNA/RNA sequencing and fluorescence in situ hybridization was employed to confirm RET fusions. The average patient age was 59, with 53% female predominance, and most were non-smokers with adenocarcinoma.<br /><br />KIF5B emerged as the most common fusion partner, followed by CCDC6 and NCOA4. Frequent mutations included TP53, CDKN2A/B, and SETD2, with a low median tumor mutational burden. A majority received combined treatment approaches (CTICI) initially, achieving an overall response rate (ORR) of 43.5%, and a median progression-free survival (PFS) of 7.7 months. The median overall survival was 30.6 months.<br /><br />Notably, patients receiving RETsi in second-line treatments showed promising PFS improvements of 17.2 months compared to other therapies. These findings suggest similar biological behavior in RET fusion positive NSCLC among Hispanic patients compared to global counterparts. However, the small sample size for RETsi treatments urges enhanced access and integration of these inhibitors within Latin America to potentially improve patient outcomes.<br /><br />This study underscores the need for regional initiatives to bolster the availability of targeted therapies like RETsi, which demonstrate significant efficacy in improving survival metrics in a subset of patients with RET fusion-positive NSCLC.

Asset Subtitle

Liliana Gutierrez

Keywords

Hispanic patients

non-small cell lung cancer

RET fusions

Latin America

targeted therapies

tyrosine kinase inhibitors

molecular profiling

KIF5B

progression-free survival

RET selective inhibitors